Treatment Patterns and Clinical Outcomes among Advanced NSCLC Patients with EGFR exon 20 Insertion Mutations in China

被引：0
|
作者：
Wang, Y. [1 ]
Lin, H. M. [2 ]
Ning, N. [3 ]
Du, F. [4 ]
Gao, X. [3 ]
Dong, Q. [2 ]
Yang, G. [1 ]
Xu, H. [5 ]
He, Y. [6 ]
Zhou, C. [6 ]
机构：
[1] Natl Clin Res Ctr Canc, Canc Hosp, Natl Canc Ctr, Dept Med Oncol, Beijing, Peoples R China
[2] Takeda Dev Ctr Amer Inc, Lexington, MA USA
[3] OPEN Hlth, Bernardsville, NJ USA
[4] OPEN Hlth, Shanghai, Peoples R China
[5] Chinese Acad Med Sci & Peking Uni, Canc Hosp, Natl Clin Res Ctr Canc, Dept Comprehens Oncol,Natl Canc Ctr, Beijing, Peoples R China
[6] Shanghai Pulm Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Non-small cell lung cancer in China; Treatment patterns; Clinical outcomes;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP10.01-17
引用
收藏
页码：S609 / S609
页数：1
相关论文
共 50 条
  • [21] Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
    Zhang, Shannon S.
    Zhu, Viola W.
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 61 - 65
  • [22] Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
    Lv, D.
    Lin, L.
    Wu, X.
    Yan, S.
    Ge, H.
    Yan, Z.
    Wang, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S634 - S634
  • [23] Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
    Lin, Ling
    Wu, Xiaomai
    Yan, Shuangquan
    Zhu, Yefei
    Yan, Zhengqing
    Lv, Dongqing
    Ge, Hongfei
    ONCOTARGETS AND THERAPY, 2020, 13 : 9753 - 9757
  • [24] EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer
    Leal, Jose Luis
    Alexander, Marliese
    Itchins, Malinda
    Wright, Gavin M.
    Kao, Steven
    Hughes, Brett G. M.
    Pavlakis, Nick
    Clarke, Stephen
    Gill, Anthony J.
    Ainsworth, Hannah
    Solomon, Benjamin
    John, Thomas
    CLINICAL LUNG CANCER, 2021, 22 (06) : E859 - E869
  • [25] Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison
    Ou, Sai-Hong I.
    Lin, Huamao M.
    Hong, Jin-Liern
    Yin, Yu
    Jin, Shu
    Lin, Jianchang
    Mehta, Minal
    Zhang, Pingkuan
    Nguyen, Danny
    Neal, Joel W.
    LUNG CANCER, 2023, 179
  • [26] Online CME Improves Clinicians' Ability to Identify and Manage Patients with NSCLC and EGFR Exon 20 Insertion Mutations
    Worst, M. A.
    Small, A.
    Kadkhoda, H.
    Reid, K.
    Cannon, M.
    Furedy, A.
    Sarris, A.
    Hsiao, S.
    Camidge, D. R.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S457 - S458
  • [27] Characterization of EGFR Exon 18 and 20 Mutations in NSCLC
    Farooqi, M.
    Oliver, D.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2014, 16 (06): : 757 - 757
  • [28] PORTUGUESE CLINICAL PRACTICE IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATIONS
    Pinheiro, B.
    Carvalho, P.
    Silva Miguel, L.
    Rodrigues, A.
    Teixeira, E.
    Barata, F.
    da Luz, R.
    Hespanhol, V
    Lopes, R.
    Santos, S.
    Borges, M.
    VALUE IN HEALTH, 2022, 25 (12) : S286 - S286
  • [29] Approval for RYBREVANT® (Amivantamab) in Patients with advanced NSCLC and activating EGFR Exon 20 Insertion Mutations after Failure of platinum-based Therapy
    不详
    ACTA HAEMATOLOGICA, 2022, 145 (02) : 230 - 230
  • [30] Anti-angiogenic Therapy or Immunotherapy? A Multicenter Study of Patients with Advanced NSCLC with EGFR / HER2 exon 20 Insertion Mutations
    Chu, T.
    Li, J.
    Xie, M.
    Zhao, R.
    Qiang, H.
    Chang, Q.
    Qian, J.
    Lu, H.
    Shen, Y.
    Han, Y.
    Su, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S628 - S628
12345